Abstract
Drug selection for the acute treatment of migraine is based on comorbid disorders, coexistent diseases, and the patient’s pain profile and specific needs and expectations. Patients should be instructed to tailor their treatment strategy to meet their specific needs by varying their medications according to pain intensity. This will aid in successful headache management, by increasing compliance and decreasing disability and cost.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Lipton RB, Stewart WF, Sawyer J: Stratified care is a more effective migraine treatment strategy than stepped care: results of a randomised clinical trial [abstract]. Neurology 2000, 54:A14.
Rozen TD: Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology 2000, 55:732–733.
Kaube H, Herzog J, Kaufer T, et al.: Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000, 55:139–141.
Wolf T, Lindauer U, Villringer A, Dirnagl U: Excessive oxygen or glucose supply does not alter the blood flow response to somatosensory stimulation or spreading depression in rats. Brain Res 1997, 761:290–299.
Silberstein SD, Rosenberg J: Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000, 54:1553. Provides the results of The US Headache Consortium, which met to discuss and develop guidelines for the diagnosis and treatment of headache.
Lipton RB: Disability assessment as a basis for stratified care. Cephalalgia 1998, 18:40–46.
Lewis TA, Solomon GD: Advances in migraine management. Cleve Clin J Med 1995, 148–155.
Lipton RB, Silberstein S: The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology 2000, in press. Presents the results of a randomized trial to evaluate strategies of care: DISC. In this study stratified care based on disability assessment with the MIDAS questionnaire is compared with two forms of step-care.
Stewart WF, Lipton RB, Whyte J, et al.: An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999, 53:988–994. The MIDAS instrument is a five-item questionnaire developed to measure headache-related disability. The authors present the result of an international population-based study to assess the reliability of a disability-related illness severity score for migraine. The reliability and internal consistency of the MIDAS score are similar to that of a previous questionnaire (Headache Impact Questionnaire), but MIDAS requires fewer questions, is easier to score, and provides intuitively meaningful information on lost days of activity in three domains.
Tepper S, Meddis D: Reducing the cost of impairment of normal activities due to migraine: a stratified care approach. Headache 2000, in press.
Silberstein SD: Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology 2000, 55:754–762.
Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 8(suppl:7):1–96.
Silberstein SD, Lipton RB: Chronic Daily Headache. In Headache, edn 1. Edited by Goadsby PJ, Silberstein SD. Boston: Butterworth-Heinemann; 1997:201–225.
Waelkens J: Warning symptoms in migraine: characteristics and therapeutic implications. Cephalalgia 1985, 5:223–228.
Cady RK, Wendt JK, Kirchner JR, et al.: Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991, 265:2831–2835.
Peikert A, Becker WJ, Ashford EA, et al.: Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. Eur J Neurol 1999, 6:43–49.
Pfaffenrath V, Cunin G, Sjonell G, Prendergast S: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998, 38:184–190. Provides the results of a multinational double-blind trial in which patients are treated up to three migraine attacks with sumatriptan 25 mg, 50 mg, 100 mg, or placebo, to define the optimum doses of oral sumatriptan and evaluate the efficacy and tolerability of three doses of sumatriptan.
Cady RK, Sheftell F, Lipton RB, et al.: Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000, 22:1035–1048.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rio, M.S.d., Silberstein, S. How to pick optimal acute treatment for migraine headache. Current Science Inc 5, 170–178 (2001). https://doi.org/10.1007/s11916-001-0085-z
Issue Date:
DOI: https://doi.org/10.1007/s11916-001-0085-z